Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1025 of 3499 entries
View as:

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00433381 Org: User:
Start: 03/01/07 End: 02/16/11 Due: 02/16/12

Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

Phase: N/A Priority: Normal
NCT ID: NCT00923026 Org: User:
Start: 06/15/09 End: - Due: -

Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00132002 Org: User:
Start: 06/30/05 End: 01/31/08 Due: 01/31/09

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00514137 Org: User:
Start: 09/30/07 End: 08/31/10 Due: 08/31/11

Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00030537 Org: User:
Start: 11/30/01 End: 03/31/03 Due: 03/31/04

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00880282 Org: User:
Start: 04/30/09 End: - Due: -

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00086567 Org: User:
Start: 12/12/05 End: - Due: -

Tissue Collection for Studies of Lymph Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01676805 Org: User:
Start: 09/21/12 End: - Due: -

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03076554 Org: User:
Start: 04/19/17 End: 06/30/26 Due: 06/30/27

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase: N/A Priority: Normal
NCT ID: NCT04339777 Org: User:
Start: 09/22/20 End: 11/30/27 Due: 11/30/28

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00103272 Org: User:
Start: 04/30/05 End: - Due: -

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Phase: N/A Priority: Normal
NCT ID: NCT04235764 Org: User:
Start: 09/09/20 End: 09/30/27 Due: 09/30/28

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03770260 Org: User:
Start: 02/10/20 End: 07/06/23 Due: 07/06/24

Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test

Phase: N/A Priority: Normal
NCT ID: NCT02734303 Org: User:
Start: 03/17/16 End: 12/01/19 Due: 12/01/20

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase: N/A Priority: Normal
NCT ID: NCT02465060 Org: User:
Start: 08/17/15 End: 12/31/25 Due: 12/31/26

ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01154426 Org: User:
Start: 05/31/10 End: 10/31/13 Due: 10/31/14

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00001582 Org: User:
Start: 06/07/97 End: 03/17/23 Due: 03/17/24

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Phase: N/A Priority: Normal
NCT ID: NCT02210858 Org: User:
Start: 05/31/00 End: 03/31/17 Due: 03/31/18

Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium

Phase: N/A Priority: Normal
NCT ID: NCT00559767 Org: User:
Start: 06/30/06 End: 04/10/12 Due: 04/10/13

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT00042991 Org: User:
Start: 07/31/02 End: 03/31/10 Due: 03/31/11

Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT00340119 Org: User:
Start: 03/21/05 End: 03/01/12 Due: 03/01/13

International Cooperation for Post-Cherynobyl NIS Thyroid Tissue and Data Banks

Phase: N/A Priority: Normal
NCT ID: NCT00339274 Org: User:
Start: 10/14/99 End: 03/16/12 Due: 03/16/13

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Phase: N/A Priority: Normal
NCT ID: NCT03180034 Org: User:
Start: 11/29/17 End: 08/01/25 Due: 08/01/26

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00068783 Org: User:
Start: 10/31/03 End: - Due: -

Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00001561 Org: User:
Start: 11/30/96 End: 09/30/05 Due: 09/30/06